The company has received approval from the US Food and Drug Administration to market a generic version of Eli Lilly and Company's Adcirca tablets in 20 mg strength.
Drug firm Lupin on February 7 said it has received approval from the US health regulator to market a generic version of Tadalafil tablets, used to treat pulmonary arterial hypertension.
The company has received approval from the US Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company's Adcirca tablets in 20 mg strength, Lupin said in a statement.
It is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability.
As per IQVIA MAT December 2018 data, Lupin said, the Tadalafil tablets, 20 mg had annual sales of around USD 474.3 million in the US.Lupin shares were trading 2.42 percent down at Rs 821.85 apiece on the BSE.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.